stimulus funding

The final year of Canada's Economic Action Plan to stimulate the economy has $160 million more marked for renewing federal labs.

Critical Path Institute and Roche's Ventana Medical Systems will lead the effort to develop the lab, which aims to advance personalized medicine in the Grand Canyon State by developing standards and best practices for accurately identifying biomarkers of patients.

CSHL secured $23.4 million of stimulus funding in 19 awards. The largest award, at more than $4.7 million over two years from the National Cancer Institute, funded the creation of a Molecular Target Discovery and Development Center.

The company will use the funds to continue to support The Cancer Genome Atlas's Data Coordinating Center.

Maven will use the funding to further build out its technology for label-free protein microarrays and cell-based assays and commercial products.

SAIC-Frederick is seeking a subcontractor to run a Comprehensive Data Resource to support the biorepository and biospecimen research programs.

Akonni is developing a multi-drug resistant/extensively drug-resistant (MDR/XDR) genotyping testing technology for the point-of-care setting.

The funding will go toward a new high performance computing facility to help carry out better-quality genome assembly computation.

The partners will use Complete Genomics' sequencing and bioinformatics services to analyze 50 tumor-normal pairs.

In interviews this past week, officials at three research institutes said that the end of ARRA funding is not expected to hinder their research efforts, while two other institutes receiving funding from the stimulus measure held off on commenting.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.